Are there still indications for total pancreatectomy?
M Del Chiaro, E Rangelova, R Segersvärd, U Arnelo - Updates in surgery, 2016 - Springer
Total pancreatectomy is associated with short-and long-term high complication rate and
without evidence of oncologic advantages. Several metabolic consequences are co-related …
without evidence of oncologic advantages. Several metabolic consequences are co-related …
Neoadjuvant treatment in locally advanced pancreatic cancer (LAPC) patients with FOLFIRINOX or gemcitabine nabpaclitaxel: a single-center experience and a …
F Napolitano, L Formisano, A Giardino, R Girelli… - Cancers, 2019 - mdpi.com
The optimal therapeutic strategy for locally advanced pancreatic cancer patients (LAPC) has
not yet been established. Our aim is to evaluate how surgery after neoadjuvant treatment …
not yet been established. Our aim is to evaluate how surgery after neoadjuvant treatment …
Percutaneous image-guided irreversible electroporation for the treatment of unresectable, locally advanced pancreatic adenocarcinoma
G Narayanan, PJ Hosein, IC Beulaygue, T Froud… - Journal of Vascular and …, 2017 - Elsevier
Purpose To describe safety and effectiveness of percutaneous irreversible electroporation
(IRE) for treatment of unresectable, locally advanced pancreatic adenocarcinoma (LAPC) …
(IRE) for treatment of unresectable, locally advanced pancreatic adenocarcinoma (LAPC) …
DNA methyltransferase mediates the hypermethylation of the microRNA 34a promoter and enhances the resistance of patient-derived pancreatic cancer cells to …
Y Ma, N Chai, Q Jiang, Z Chang, Y Chai, X Li… - Pharmacological …, 2020 - Elsevier
DNA methyltransferase (DNMT) participates in the transformation or progression of human
cancers by mediating the hypermethylation of cancer suppressors. However, the regulatory …
cancers by mediating the hypermethylation of cancer suppressors. However, the regulatory …
Comparison of endoscopic ultrasound tissue acquisition methods for genomic analysis of pancreatic cancer
S Elhanafi, N Mahmud, N Vergara… - Journal of …, 2019 - Wiley Online Library
Abstract Background and Aim Tumor genoty** may allow for improved prognostication
and targeted therapy for pancreatic ductal adenocarcinoma (PDAC). We aimed to compare …
and targeted therapy for pancreatic ductal adenocarcinoma (PDAC). We aimed to compare …
M6A regulatory genes play an important role in the prognosis, progression and immune microenvironment of pancreatic adenocarcinoma
F Xu, Z Zhang, M Yuan, Y Zhao, Y Zhou, H Pei… - Cancer …, 2021 - Taylor & Francis
The specific roles of N6-methyladenosine (m6A) regulatory genes in pancreatic
adenocarcinoma (PAAD) have not been fully elucidated. In present study, a novel risk …
adenocarcinoma (PAAD) have not been fully elucidated. In present study, a novel risk …
Efficacy and feasibility of stereotactic radiotherapy after folfirinox in patients with locally advanced pancreatic cancer (LAPC-1 trial)
M Suker, JJ Nuyttens, FALM Eskens… - …, 2019 - thelancet.com
Background We conducted a multicentre phase II trial to investigate feasibility and antitumor
activity of sequential FOLFIRINOX and Stereotactic Body Radiotherapy (SBRT) in patients …
activity of sequential FOLFIRINOX and Stereotactic Body Radiotherapy (SBRT) in patients …
m6A Methyltransferase METTL14-Mediated Upregulation of Cytidine Deaminase Promoting Gemcitabine Resistance in Pancreatic Cancer
C Zhang, S Ou, Y Zhou, P Liu, P Zhang, Z Li… - Frontiers in …, 2021 - frontiersin.org
Objective Pancreatic cancer is one of the most lethal human malignancies. Gemcitabine is
widely used to treat pancreatic cancer, and the resistance to chemotherapy is the major …
widely used to treat pancreatic cancer, and the resistance to chemotherapy is the major …
[HTML][HTML] Perioperative and survival outcomes following neoadjuvant FOLFIRINOX versus gemcitabine abraxane in patients with pancreatic adenocarcinoma
BC Chapman, A Gleisner, D Rigg… - JOP: Journal of the …, 2018 - ncbi.nlm.nih.gov
Perioperative and Survival Outcomes Following Neoadjuvant FOLFIRINOX versus
Gemcitabine Abraxane in Patients with Pancreatic Adenocarcinoma - PMC Back to Top …
Gemcitabine Abraxane in Patients with Pancreatic Adenocarcinoma - PMC Back to Top …
The platelet pannexin 1-IL-1β axis orchestrates pancreatic ductal adenocarcinoma invasion and metastasis
H Li, W Jiang, SR Zhang, PC Li, TJ Li, W **, HX Xu… - Oncogene, 2023 - nature.com
We aimed to investigate the protumor mechanisms of platelets in pancreatic ductal
adenocarcinoma (PDAC). Serum samples were collected from 656 PDAC patients and 3105 …
adenocarcinoma (PDAC). Serum samples were collected from 656 PDAC patients and 3105 …